Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orchestra BioMed HoldingsOBIO +7.00%42 Quick Ratio is 8.24 as of Jun. 2026, which is 67% above its 10-year median of 4.93. GuruFocus rates OBIO with a GF Score™ of 42/100 and a GF Value™ of $31.58 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,408 Biotechnology companies, Orchestra BioMed Holdings ranks better than 74.01% on this metric.
Orchestra BioMed Holdings (NAS:OBIO) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Orchestra BioMed Holdings Quick Ratio Related Terms
Orchestra BioMed Holdings Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Orchestra BioMed Holdings's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orchestra BioMed Holdings Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Orchestra BioMed Holdings's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Orchestra BioMed Holdings's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Orchestra BioMed Holdings's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orchestra BioMed Holdings (OBIO) has a Quick Ratio of 8.24 as of Jun. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Orchestra BioMed Holdings and its competitors. This is 67% above median its historical median of 4.93. Over the past decade, Orchestra BioMed Holdings' Quick Ratio has ranged from 0.92 to 10.75. According to the industry distribution chart, Orchestra BioMed Holdings ranks #366 out of 1408 companies in the Biotechnology industry, placing it in the top 26%.
Is Orchestra BioMed Holdings' Quick Ratio too high?
Orchestra BioMed Holdings' current Quick Ratio of 8.24 is 67% above median its 10-year median of 4.93. Over the past 10 years, this metric has ranged from a low of 0.92 to a high of 10.75. The Biotechnology industry median Quick Ratio is 3.59. Orchestra BioMed Holdings' value of 8.24 is 129.8% above this industry median. Based on the distribution chart, Orchestra BioMed Holdings ranks #366 out of 1408 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Orchestra BioMed Holdings has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Orchestra BioMed Holdings' Quick Ratio compare to CYDY and IRD?
According to the Biotechnology industry distribution chart, Orchestra BioMed Holdings ranks #366 out of 1408 companies for Quick Ratio. This puts Orchestra BioMed Holdings in the upper half of its industry. The industry median Quick Ratio is 3.59. Orchestra BioMed Holdings' value of 8.24 is 129.8% above this benchmark. Historically, Orchestra BioMed Holdings' own Quick Ratio has ranged from 0.92 to 10.75 over the past decade. While the company's 10-year median is 4.93 vs. the industry median of 3.59, Orchestra BioMed Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,408 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orchestra BioMed Holdings's current Quick Ratio of 8.24 is 129.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Orchestra BioMed Holdings and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orchestra BioMed Holdings's current Quick Ratio is 8.24, which is 67% above median its own 10-year median of 4.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orchestra BioMed Holdings stock overvalued right now?
Based on GuruFocus' analysis, Orchestra BioMed Holdings (OBIO) is currently considered Possible Value Trap. The stock's GF Value™ is $31.58, compared to a current price of $5.81 — trading 81.6% below its estimated fair value. The current Quick Ratio is 8.24, which is 67% above median its 10-year median of 4.93 and 129.8% above the Biotechnology industry median of 3.59. Orchestra BioMed Holdings' overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Orchestra BioMed Holdings (OBIO), the current Quick Ratio is 8.24 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orchestra BioMed Holdings (OBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Orchestra BioMed Holdings stock appears to be undervalued.
The current stock price of $5.81 is trading 81.6% below its estimated GF Value™ of $31.58.
GuruFocus considers Orchestra BioMed Holdings to be Possible Value Trap.
Key valuation signals for OBIO:
Quick Ratio: 8.24 (67% above median its 10-year median of 4.93)
GF Value™: $31.58 vs. price of $5.81 (81.6% below fair value)
Industry Position: 129.8% above the Biotechnology median (#366 of 1408)
No single metric tells the full story. See the OBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
42GF Score
Get the complete analysis for OBIO
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OBIO has been successfully added to your 
